Becker's Hospital Review6d
Big 3 PBM formularies favor private-label biosimilars
Discover how the three largest pharmacy benefit managers are rejecting biosimilars from their formularies, except for their own private-label drugs.
Heartland13d
What the FDA Gets Wrong About Drug Ads – Commentary
Drug companies in the U.S. are spending $4 billion a year on TV ads touting the drug benefits with rapid-fire list of ...
MM&M12d
Rx Rundown: Johnson & Johnson, Eli Lilly, the FDA and more
The FDA proposed to require a front-of-package (FOP) nutrition label for most packaged foods. FDA accepted Biogen and Eisai’s Leqembi (lecanemab-irmb) Biologics License Application for subcutaneous ...
JD Supra11d
FDA Issues ACNU Final Rule Establishing New Requirements for Nonprescription Drugs with an Additional Condition for Nonprescription Use
The US Food and Drug Administration (FDA)’s recently issued final rule establishing application, labeling, and postmarketing reporting ...
Face Moisturizer Recalled Nationwide as FDA Sets Risk Level
On December 23, First Aid Beauty recalled 2,756 jars of its Ultra Repair Cream. According to the FDA, a deviation from ...
Hosted on MSN1d
MSD wins FDA priority review for Welireg in rare endocrine cancer
The US Food and Drug Administration (FDA) will soon decide on whether to expand the label of MSD’s Welireg (belzutifan) to ...
Hosted on MSN4d
First Aid Beauty Recalls Face Moisturizer as FDA Labels It as ‘Class II' Risk
First Aid Beauty has recently recalled one of its moisturizers. Now many customers are eager to find out more about the ...
Targeted Oncology9h
FDA Grants Belzutifan Priority Review For Advanced Pheochromocytoma and Paraganglioma
The FDA granted priority review for belzutifan for treating advanced pheochromocytoma and paraganglioma, with a PDUFA date ...